12:00 AM
 | 
Oct 08, 2007
 |  BioCentury  |  Product Development

12 + 23 = psoriatic relief

Johnson & Johnson thinks ustekinumab, a first-in-class monoclonal antibody against IL-12 and IL-23, could represent a paradigm shift in the treatment of psoriasis. Based on data presented last week, the MAb appears to have efficacy as good as the best marketed biologics plus improved convenience and a better safety profile.

At the World Congress of Dermatology in Buenos Aires, the company reported ustekinumab met the primary endpoint of PASI 75 score in a Phase III trial in moderate to severe plaque psoriasis, setting the stage for the submission of marketing applications in the U.S. and Europe this year.

Jerome Boscia, SVP of clinical R&D at JNJ's Centocor Inc. unit, told BioCentury the original concept for ustekinumab (CNTO 1275) was to knock out interleukin-12, a cytokine known to play an important role in skin inflammation through its modulation of T cells, by targeting the p40 subunit....

Read the full 723 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >